Human Vaccines Market Share
ID: MRFR/Pharma/1984-HCR
200 Pages
October 2025
Human Vaccines Market Research Report By Vaccine Type (Inactivated, Live Attenuated, Subunit, Recombinant, Toxoid), By Application (Preventive Vaccines, Therapeutic Vaccines, Travel Vaccines, Influenza Vaccines), By Administration Route (Intramuscular, Subcutaneous, Oral, Intradermal), By Target Diseases (Infectious Diseases, Oncological Diseases, Autoimmune Diseases) and By Regional (North Ame...
Market Summary
As per Market Research Future Analysis, the Human Vaccines Market is projected to grow significantly, driven by the increasing prevalence of infectious diseases and heightened public awareness of vaccination benefits. The market is expected to expand from 50.22 USD Billion in 2025 to 1.23 USD Billion by 2035, reflecting a CAGR of 4.14% during the forecast period. Key drivers include substantial investments in research and development, public-private partnerships, and advancements in vaccine technology, such as mRNA and personalized vaccines.
Key Market Trends & Highlights
The Global Human Vaccines Market is witnessing transformative trends that are shaping its future.
- Market Size in 2024: 0.67 USD Billion; Expected to reach 1.23 USD Billion by 2035. Inactivated vaccines valued at 15.0 USD Billion in 2024, projected to grow to 23.0 USD Billion by 2035. Public awareness campaigns have increased immunization coverage for DTP vaccines to over 85% globally. North America leads the market with a valuation of 20.0 USD Billion in 2024, expected to grow to 32.0 USD Billion by 2035.
Market Size & Forecast
| 2024 Market Size | USD 0.67 Billion |
| 2035 Market Size | USD 1.23 Billion |
| CAGR (2025-2035) | 5.72% |
| Largest Regional Market Share in 2024 | North America. |
Major Players
<p>Key Companies include Pfizer, Merck and Co, AbbVie, Roche, Gilead Sciences, Johnson and Johnson, Bristol Myers Squibb, Novartis, Regeneron Pharmaceuticals, Bayer, Moderna, AstraZeneca, GlaxoSmithKline, Sanofi.</p>
Market Trends
The Global Human Vaccines Market is witnessing significant trends driven by various market factors. A key market driver is the increasing prevalence of infectious diseases and the need for preventative healthcare measures. With growing awareness of vaccination benefits, governments and healthcare organizations are investing in vaccination programs to prevent outbreaks and enhance public health.
This heightened focus on preventive healthcare is leading nations to support initiatives aimed at increasing vaccination coverage and developing innovative vaccines. Opportunities to be explored in this market include advancements in vaccine technology, such as mRNA technology and personalized vaccines.
As researchers continue to innovate, there is potential for the introduction of new and effective vaccine formulations that cater to specific populations and evolving pathogens. Furthermore, as global travel increases and disease patterns change, there is an increasing demand for vaccines that address emerging infectious diseases, presenting a chance for companies to develop specialized products.
In recent times, trends show a significant increase in public-private partnerships to facilitate vaccine research and distribution, as seen during the COVID-19 pandemic. This collaboration has not only expedited vaccine development timelines but has also highlighted the importance of global cooperation in addressing health crises.
Furthermore, the push towards universal vaccination programs to ensure equitable access across diverse populations has gained momentum, reflecting a commitment to global health security. Overall, these trends underscore a dynamic environment where innovation, collaboration, and public health priorities shape the future of the Global Human Vaccines Market.
<p>The Global Human Vaccines Market is poised for robust growth, driven by increasing public health initiatives and a heightened focus on preventive healthcare measures.</p>
World Health Organization (WHO)
Human Vaccines Market Market Drivers
Increasing Global Vaccination Coverage
The Global Human Vaccines Market Industry is experiencing growth due to the increasing emphasis on vaccination coverage across various populations. Governments worldwide are implementing policies aimed at enhancing immunization rates, particularly in developing regions. For instance, initiatives by the World Health Organization focus on achieving universal vaccination coverage, which is projected to significantly impact market dynamics. As of 2024, the market is valued at approximately 48.2 USD Billion, reflecting the importance of vaccination in public health strategies. This trend is expected to continue, with a projected market value of 78.5 USD Billion by 2035, indicating a sustained commitment to improving global health outcomes.
Market Segment Insights
Human Vaccines Market Vaccine Type Insights
<p>The Global Human Vaccines Market is poised for considerable growth, with a notable focus on the Vaccine Type segment, which includes various classifications like Inactivated, Live Attenuated, Subunit, Recombinant, and Toxoid vaccines. The overall market is expected to witness a substantial rise, with projections indicating a value of 50.22 USD Billion in 2024 and reaching 78.5 USD Billion by 2035. Within this landscape, the Inactivated segment holds the majority, valued at 15.0 USD Billion in 2024 and projected to grow to 23.0 USD Billion by 2035.</p>
<p>This segment is vital due to its effectiveness in immunizing against a range of diseases without causing the infection itself, making it a safe choice for broad population use. Following closely is the Live Attenuated segment, expected to be valued at 10.0 USD Billion in 2024 and rise to 15.5 USD Billion by 2035. Live Attenuated vaccines are significant as they offer robust immunity and often require fewer doses, thereby ensuring better compliance among different demographics. </p>
<p>The Subunit vaccines are valued at 8.0 USD Billion in 2024, increasing to 12.0 USD Billion by 2035, which makes them critical due to their ability to use only specific parts of the virus or bacteria, reducing side effects while maintaining efficacy.</p>
Human Vaccines Market Application Insights
<p>This segment encompasses critical applications including Preventive Vaccines, Therapeutic Vaccines, Travel Vaccines, and Influenza Vaccines. Preventive Vaccines are crucial in preventing infectious diseases, thus significantly impacting global health outcomes. Furthermore, Therapeutic Vaccines are gaining traction in treating chronic diseases and cancers, leading to innovations in Research and Development.</p>
<p>Travel Vaccines cater to health-conscious travelers, promoting safety and disease prevention across borders, while Influenza Vaccines remain essential given the seasonal outbreaks, ensuring community health is prioritized. With such diverse applications, the Global Human Vaccines Market revenue is set to expand, backed by rising public health initiatives and awareness around vaccine benefits, despite challenges such as logistics and public skepticism. Understanding this landscape through Global Human Vaccines Market segmentation is vital for stakeholders to harness opportunities and enhance vaccine accessibility.</p>
Human Vaccines Market Administration Route Insights
<p>The Administration Route plays a crucial role in this market, as it encompasses various methods used to deliver vaccines effectively. This segmentation includes routes such as Intramuscular, Subcutaneous, Oral, and Intradermal administration, each of which presents unique advantages. Intramuscular administration is particularly notable for its rapid immune response, making it a preferred choice for many vaccines, including those targeting diseases like influenza and COVID-19</p>
<p>.Subcutaneous routes are gaining traction due to their ease of administration, especially for patients who require self-administration. Oral vaccination presents an innovative approach that can improve accessibility and adherence, while Intradermal administration is being explored for its potential to reduce vaccine dosages and improve immunogenicity. As the Global Human Vaccines Market data shows, the increasing focus on vaccination programs worldwide, along with advances in vaccine delivery technologies, is a driving force behind the growth and significance of these administration routes.</p>
<p>The ongoing challenges of vaccine hesitancy and logistical issues create pathways for innovative solutions in this sector. The Global Human Vaccines Market statistics suggest that the various administration methods are integral to achieving widespread vaccine coverage and combating infectious diseases on a global scale.</p>
Human Vaccines Market Target Diseases Insights
<p>The landscape is primarily shaped by various diseases, including Infectious Diseases, Oncological Diseases, and Autoimmune Diseases. <a href="https://www.marketresearchfuture.com/reports/infectious-disease-drug-market-43143">Infectious Disease vaccines</a> remain crucial due to their role in preventing outbreaks and protecting public health, while Oncological Diseases vaccines are gaining importance in cancer prevention and treatment, reflecting advancements in Research and Development.</p>
<p>Autoimmune Diseases, often complex and diverse, present significant challenges for vaccine development yet represent a growing area of interest for addressing chronic health issues. The increasing prevalence of these diseases, coupled with technological advancements and a growing understanding of the immune system, contributes to the market growth. With a compound annual growth rate of 4.14 expected for the period from 2025 to 2035, the sector is well-positioned to adapt to emerging health challenges while continuously making strides in vaccine effectiveness and safety.</p>
<p>The Global Human Vaccines Market statistics indicate a trend toward personalized and targeted therapies, emphasizing the importance of addressing diverse health needs on a global scale.</p>
Get more detailed insights about Human Vaccines Market Research Report - Forecast to 2034
Regional Insights
The Global Human Vaccines Market is characterized by diverse regional dynamics shaping its growth trajectory. In 2024, North America leads with a valuation of 20.0 USD Billion, expected to grow to 32.0 USD Billion by 2035, reflecting significant investments in Research and Development and robust healthcare infrastructure. Europe follows with a market value of 12.5 USD Billion in 2024, projected to rise to 20.0 USD Billion, highlighting the region's focus on innovation and advanced immunization strategies.
The Asia-Pacific (APAC) region is projected to reach 10.0 USD Billion in 2024, with growth anticipated to 15.0 USD Billion, driven by a rapidly expanding population and increasing healthcare accessibility.South America is valued at 4.0 USD Billion in 2024, growing to 6.0 USD Billion, showcasing improvements in vaccination coverage amidst economic advancements. The Middle East and Africa (MEA) hold a current market value of 3.72 USD Billion, progressing to 5.5 USD Billion, as investments in healthcare infrastructure rise, enhancing vaccine delivery systems.
The dominance of North America, in particular, underscores the significant role of regulatory frameworks and funding in vaccine development, while the growth in APAC indicates a burgeoning demand for vaccines amid increasing healthcare expenditure.
Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review
Key Players and Competitive Insights
The Global Human Vaccines Market is characterized by robust competition and constant innovation, driven by the critical importance of vaccines in preventing diseases and safeguarding public health. As the market expands, various pharmaceutical companies vie for leadership, investing heavily in research and development to create more effective vaccine solutions.
Factors such as increasing prevalence of infectious diseases, emerging global health threats, and the rising demand for vaccines worldwide are shaping the competitive landscape. As a result, companies are not only focusing on advanced research but also forming strategic alliances and partnerships, which enhance their capabilities in delivering innovative vaccine options to meet global health needs.
Pfizer has established itself as a formidable player in the Global Human Vaccines Market, underpinned by its extensive portfolio and deep-rooted commitment to vaccine development. The company’s strengths lie in its advanced technological platforms and strong RD capabilities, which allow it to deliver a wide range of vaccines targeting various infectious diseases.
Pfizer’s global presence is reinforced through its strategic partnerships, collaborations with healthcare organizations, and robust distribution networks, enabling it to reach diverse markets effectively. The company's significant investment in innovative vaccine research has resulted in breakthroughs that have addressed urgent global health concerns, further solidifying its position in the competitive landscape.
Merck and Co a significant footprint in the Global Human Vaccines Market, focusing on the development of innovative vaccines and therapeutic solutions for infectious diseases. Renowned for its key products, Merck offers vaccines that target diseases such as HPV, measles, and influenza. The company has been proactive in expanding its market presence through strategic mergers and acquisitions, allowing it to integrate novel technologies and enhance its research capabilities.
Merck’s strong emphasis on vaccine development is reflected in its commitment to global health initiatives aimed at increasing accessibility and expanding immunization programs. Its well-established reputation for high-quality products and strong pipeline of vaccine candidates positions Merck as a leader in the market committed to advancing public health through continuous innovation and responsive product offerings.
Key Companies in the Human Vaccines Market market include
Industry Developments
Recent developments in the Global Human Vaccines Market have been significantly influenced by various factors, including the ongoing response to infectious diseases and advancements in vaccine technology. In October 2023, Pfizer announced a collaboration with Moderna to enhance mRNA vaccine production efficiency, reflecting an industry trend toward partnerships for rapid vaccine development. Meanwhile, Merck and Co confirmed their investment in next-generation vaccine platforms to combat emerging pathogens, showcasing a commitment to innovation in vaccine efficacy and safety.
Currently, companies like Gilead Sciences and Johnson and Johnson are focusing on expanding their pipeline, especially in therapeutic vaccines targeting HIV and cancer, while Roche and Novartis are investing in biopharmaceuticals to enhance immunogenicity. Notably, GlaxoSmithKline has reported a substantial increase in vaccine sales, attributing this to rising vaccination rates globally.
In the past two to three years, the market has seen significant growth due to increased vaccination campaigns, particularly against COVID-19, with AstraZeneca and Sanofi making strides in vaccine distribution. The combined efforts of these leading firms illustrate a dynamic landscape in the Global Human Vaccines Market, emphasizing innovation and strategic collaborations to address public health challenges.
Future Outlook
Human Vaccines Market Future Outlook
<p>The Human Vaccines Market is projected to grow at a 5.72% CAGR from 2025 to 2035, driven by technological advancements, increasing vaccination awareness, and expanding global health initiatives.</p>
New opportunities lie in:
- <p>Invest in mRNA vaccine technology for rapid response to emerging pathogens. Develop combination vaccines to enhance immunization coverage and patient compliance. Leverage digital health platforms for vaccine tracking and patient engagement.</p>
<p>By 2035, the Human Vaccines Market is expected to be robust, reflecting substantial advancements and increased global health commitments.</p>
Market Segmentation
Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
Human Vaccines Market Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
Human Vaccines Market Application Outlook
- Preventive Vaccines
- Therapeutic Vaccines
- Travel Vaccines
- Influenza Vaccines
Human Vaccines Market Vaccine Type Outlook
- Inactivated
- Live Attenuated
- Subunit
- Recombinant
- Toxoid
Human Vaccines Market Target Diseases Outlook
- Infectious Diseases
- Oncological Diseases
- Autoimmune Diseases
Human Vaccines Market Administration Route Outlook
- Intramuscular
- Subcutaneous
- Oral
- Intradermal
Report Scope
| Report Attribute/Metric | Details |
| Market Size 2024 | 48.22(USD Billion) |
| Market Size 2025 | 50.22(USD Billion) |
| Market Size 2035 | 1.23 (USD Billion) |
| Compound Annual Growth Rate (CAGR) | 5.72% (2025 - 2035) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Pfizer, Merck and Co, AbbVie, Roche, Gilead Sciences, Johnson and Johnson, Bristol Myers Squibb, Novartis, Regeneron Pharmaceuticals, Bayer, Moderna, AstraZeneca, GlaxoSmithKline, Sanofi |
| Segments Covered | Vaccine Type, Application, Administration Route, Target Diseases, Regional |
| Key Market Opportunities | Rising infectious disease outbreaks, Increasing vaccination awareness, Expansion of vaccine pipelines, Growth in healthcare funding, Advancements in vaccine technology |
| Key Market Dynamics | Increasing vaccine demand, Technological advancements, Government support and funding, Global health initiatives, Rising infectious diseases. |
| Countries Covered | North America, Europe, APAC, South America, MEA |
Market Highlights
Author
Latest Comments
John Doe
john@example.com
This is a great article! Really helped me understand the topic better.
Posted on July 23, 2025, 10:15
AM
Jane Smith
jane@domain.com
Thanks for sharing this. I’ve bookmarked it for later reference.
Posted on July 22, 2025, 7:45
PM
FAQs
What is the projected market size of the Global Human Vaccines Market by 2035?
The Global Human Vaccines Market is expected to be valued at 78.5 USD Billion by 2035.
What is the expected compound annual growth rate (CAGR) for the Global Human Vaccines Market from 2025 to 2035?
The expected CAGR for the Global Human Vaccines Market from 2025 to 2035 is 4.14%.
Which region is projected to hold the largest market share in the Global Human Vaccines Market by 2035?
North America is projected to hold the largest market share, valued at 32.0 USD Billion by 2035.
What will be the market size of Inactivated vaccines in the Global Human Vaccines Market by 2035?
The market size for Inactivated vaccines is expected to reach 23.0 USD Billion by 2035.
Who are the major players in the Global Human Vaccines Market?
Major players in the Global Human Vaccines Market include Pfizer, Merck and Co, AbbVie, and Roche among others.
What is the expected market value for the Live Attenuated vaccine segment by 2035?
The Live Attenuated vaccine segment is expected to reach a market value of 15.5 USD Billion by 2035.
How much is the market for Subunit vaccines expected to grow by 2035?
The market for Subunit vaccines is projected to grow to 12.0 USD Billion by 2035.
What is the projected market value of the Global Human Vaccines Market in 2024?
The projected market value of the Global Human Vaccines Market in 2024 is 50.22 USD Billion.
What is the expected market value for the Toxoid vaccine segment by 2035?
The Toxoid vaccine segment is anticipated to reach a market value of 11.0 USD Billion by 2035.
How will the APAC region's market size change from 2024 to 2035?
The market size in the APAC region is expected to grow from 10.0 USD Billion in 2024 to 15.0 USD Billion by 2035.
-
--- "
-
Table of Contents
-
EXECUTIVE SUMMARY
-
Market Overview
-
Key Findings
-
Market Segmentation
-
Competitive Landscape
-
Challenges and Opportunities
-
Future Outlook
-
MARKET INTRODUCTION
-
Definition
-
Scope of the study
-
Research Objective
-
Assumption
-
Limitations
-
RESEARCH METHODOLOGY
-
Overview
-
Data Mining
-
Secondary Research
-
Primary Research
-
Primary Interviews and Information Gathering Process
-
Breakdown of Primary Respondents
-
Forecasting Model
-
Market Size Estimation
-
Bottom-Up Approach
-
Top-Down Approach
-
Data Triangulation
-
Validation
-
MARKET DYNAMICS
-
Overview
-
Drivers
-
Restraints
-
Opportunities
-
MARKET FACTOR ANALYSIS
-
Value chain Analysis
-
Porter's Five Forces Analysis
-
Bargaining Power of Suppliers
-
Bargaining Power of Buyers
-
Threat of New Entrants
-
Threat of Substitutes
-
Intensity of Rivalry
-
COVID-19 Impact Analysis
-
Market Impact Analysis
-
Regional Impact
-
Opportunity and Threat Analysis
-
Human Vaccines Market, BY Vaccine Type (USD Billion)
-
Inactivated
-
Live Attenuated
-
Subunit
-
Recombinant
-
Toxoid
-
Human Vaccines Market, BY Application (USD Billion)
-
Preventive Vaccines
-
Therapeutic Vaccines
-
Travel Vaccines
-
Influenza Vaccines
-
Human Vaccines Market, BY Administration Route (USD Billion)
-
Intramuscular
-
Subcutaneous
-
Oral
-
Intradermal
-
Human Vaccines Market, BY Target Diseases (USD Billion)
-
Infectious Diseases
-
Oncological Diseases
-
Autoimmune Diseases
-
Human Vaccines Market, BY Regional (USD Billion)
-
North America
-
US
-
Canada
-
Europe
-
Germany
-
UK
-
France
-
Russia
-
Italy
-
Spain
-
Rest of Europe
-
APAC
-
China
-
India
-
Japan
-
South Korea
-
Malaysia
-
Thailand
-
Indonesia
-
Rest of APAC
-
South America
-
Brazil
-
Mexico
-
Argentina
-
Rest of South America
-
MEA
-
GCC Countries
-
South Africa
-
Rest of MEA
-
Competitive Landscape
-
Overview
-
Competitive Analysis
-
Market share Analysis
-
Major Growth Strategy in the Human Vaccines Market
-
Competitive Benchmarking
-
Leading Players in Terms of Number of Developments in the Human Vaccines Market
-
Key developments and growth strategies
-
New Product Launch/Service Deployment
-
Merger & Acquisitions
-
Joint Ventures
-
Major Players Financial Matrix
-
Sales and Operating Income
-
Major Players R&D Expenditure. 2023
-
Company Profiles
-
Pfizer
-
Financial Overview
-
Products Offered
-
Key Developments
-
SWOT Analysis
-
Key Strategies
-
Merck and Co
-
Financial Overview
-
Products Offered
-
Key Developments
-
SWOT Analysis
-
Key Strategies
-
AbbVie
-
Financial Overview
-
Products Offered
-
Key Developments
-
SWOT Analysis
-
Key Strategies
-
Roche
-
Financial Overview
-
Products Offered
-
Key Developments
-
SWOT Analysis
-
Key Strategies
-
Gilead Sciences
-
Financial Overview
-
Products Offered
-
Key Developments
-
SWOT Analysis
-
Key Strategies
-
Johnson and Johnson
-
Financial Overview
-
Products Offered
-
Key Developments
-
SWOT Analysis
-
Key Strategies
-
Bristol Myers Squibb
-
Financial Overview
-
Products Offered
-
Key Developments
-
SWOT Analysis
-
Key Strategies
-
Novartis
-
Financial Overview
-
Products Offered
-
Key Developments
-
SWOT Analysis
-
Key Strategies
-
Regeneron Pharmaceuticals
-
Financial Overview
-
Products Offered
-
Key Developments
-
SWOT Analysis
-
Key Strategies
-
Bayer
-
Financial Overview
-
Products Offered
-
Key Developments
-
SWOT Analysis
-
Key Strategies
-
Moderna
-
Financial Overview
-
Products Offered
-
Key Developments
-
SWOT Analysis
-
Key Strategies
-
AstraZeneca
-
Financial Overview
-
Products Offered
-
Key Developments
-
SWOT Analysis
-
Key Strategies
-
GlaxoSmithKline
-
Financial Overview
-
Products Offered
-
Key Developments
-
SWOT Analysis
-
Key Strategies
-
Sanofi
-
Financial Overview
-
Products Offered
-
Key Developments
-
SWOT Analysis
-
Key Strategies
-
Appendix
-
References
-
Related Reports
Human Vaccines Market Segmentation
Human Vaccines Market By Vaccine Type (USD Billion, 2019-2035)
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
Human Vaccines Market By Application (USD Billion, 2019-2035)
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
Human Vaccines Market By Administration Route (USD Billion, 2019-2035)
Intramuscular
Subcutaneous
Oral
Intradermal
Human Vaccines Market By Target Diseases (USD Billion, 2019-2035)
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
Human Vaccines Market By Regional (USD Billion, 2019-2035)
North America
Europe
South America
Asia Pacific
Middle East and Africa
Human Vaccines Market Regional Outlook (USD Billion, 2019-2035)
North America Outlook (USD Billion, 2019-2035)
North America Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
North America Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
North America Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
North America Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
North America Human Vaccines Market by Regional Type
US
Canada
US Outlook (USD Billion, 2019-2035)
US Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
US Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
US Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
US Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
CANADA Outlook (USD Billion, 2019-2035)
CANADA Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
CANADA Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
CANADA Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
CANADA Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
Europe Outlook (USD Billion, 2019-2035)
Europe Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
Europe Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
Europe Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
Europe Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
Europe Human Vaccines Market by Regional Type
Germany
UK
France
Russia
Italy
Spain
Rest of Europe
GERMANY Outlook (USD Billion, 2019-2035)
GERMANY Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
GERMANY Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
GERMANY Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
GERMANY Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
UK Outlook (USD Billion, 2019-2035)
UK Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
UK Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
UK Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
UK Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
FRANCE Outlook (USD Billion, 2019-2035)
FRANCE Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
FRANCE Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
FRANCE Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
FRANCE Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
RUSSIA Outlook (USD Billion, 2019-2035)
RUSSIA Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
RUSSIA Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
RUSSIA Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
RUSSIA Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
ITALY Outlook (USD Billion, 2019-2035)
ITALY Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
ITALY Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
ITALY Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
ITALY Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
SPAIN Outlook (USD Billion, 2019-2035)
SPAIN Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
SPAIN Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
SPAIN Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
SPAIN Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
REST OF EUROPE Outlook (USD Billion, 2019-2035)
REST OF EUROPE Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
REST OF EUROPE Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
REST OF EUROPE Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
REST OF EUROPE Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
APAC Outlook (USD Billion, 2019-2035)
APAC Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
APAC Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
APAC Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
APAC Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
APAC Human Vaccines Market by Regional Type
China
India
Japan
South Korea
Malaysia
Thailand
Indonesia
Rest of APAC
CHINA Outlook (USD Billion, 2019-2035)
CHINA Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
CHINA Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
CHINA Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
CHINA Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
INDIA Outlook (USD Billion, 2019-2035)
INDIA Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
INDIA Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
INDIA Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
INDIA Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
JAPAN Outlook (USD Billion, 2019-2035)
JAPAN Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
JAPAN Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
JAPAN Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
JAPAN Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
SOUTH KOREA Outlook (USD Billion, 2019-2035)
SOUTH KOREA Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
SOUTH KOREA Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
SOUTH KOREA Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
SOUTH KOREA Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
MALAYSIA Outlook (USD Billion, 2019-2035)
MALAYSIA Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
MALAYSIA Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
MALAYSIA Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
MALAYSIA Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
THAILAND Outlook (USD Billion, 2019-2035)
THAILAND Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
THAILAND Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
THAILAND Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
THAILAND Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
INDONESIA Outlook (USD Billion, 2019-2035)
INDONESIA Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
INDONESIA Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
INDONESIA Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
INDONESIA Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
REST OF APAC Outlook (USD Billion, 2019-2035)
REST OF APAC Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
REST OF APAC Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
REST OF APAC Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
REST OF APAC Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
South America Outlook (USD Billion, 2019-2035)
South America Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
South America Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
South America Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
South America Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
South America Human Vaccines Market by Regional Type
Brazil
Mexico
Argentina
Rest of South America
BRAZIL Outlook (USD Billion, 2019-2035)
BRAZIL Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
BRAZIL Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
BRAZIL Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
BRAZIL Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
MEXICO Outlook (USD Billion, 2019-2035)
MEXICO Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
MEXICO Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
MEXICO Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
MEXICO Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
ARGENTINA Outlook (USD Billion, 2019-2035)
ARGENTINA Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
ARGENTINA Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
ARGENTINA Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
ARGENTINA Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
REST OF SOUTH AMERICA Outlook (USD Billion, 2019-2035)
REST OF SOUTH AMERICA Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
REST OF SOUTH AMERICA Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
REST OF SOUTH AMERICA Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
REST OF SOUTH AMERICA Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
MEA Outlook (USD Billion, 2019-2035)
MEA Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
MEA Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
MEA Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
MEA Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
MEA Human Vaccines Market by Regional Type
GCC Countries
South Africa
Rest of MEA
GCC COUNTRIES Outlook (USD Billion, 2019-2035)
GCC COUNTRIES Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
GCC COUNTRIES Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
GCC COUNTRIES Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
GCC COUNTRIES Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
SOUTH AFRICA Outlook (USD Billion, 2019-2035)
SOUTH AFRICA Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
SOUTH AFRICA Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
SOUTH AFRICA Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
SOUTH AFRICA Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
REST OF MEA Outlook (USD Billion, 2019-2035)
REST OF MEA Human Vaccines Market by Vaccine Type
Inactivated
Live Attenuated
Subunit
Recombinant
Toxoid
REST OF MEA Human Vaccines Market by Application Type
Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Influenza Vaccines
REST OF MEA Human Vaccines Market by Administration Route Type
Intramuscular
Subcutaneous
Oral
Intradermal
REST OF MEA Human Vaccines Market by Target Diseases Type
Infectious Diseases
Oncological Diseases
Autoimmune Diseases
Free Sample Request
Kindly complete the form below to receive a free sample of this Report
Customer Strories
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Leave a Comment